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Objective. This study compares low dose versus aggressive inhibition of the renin angiotensin system (RAS) to treat
microalbuminuria (MA). Methods. Patients with MA after a run-in period to control BP to <130/80mmHg with 10mg benazepril
plus other drugs and HbA1c levels to <8.0% were randomized to either continue 10mg benazepril (N = 12) or to take maximal
doses of benazepril plus losartan in monthly stepwise increases to achieve normoalbuminuria (N = 11). Because MA is associated
with CVD and inﬂammation, carotid intima medial thickness (CIMT) and endothelial function by peripheral arterial tonometry
(PAT) as surrogate indices of atherosclerosis and highly sensitive C-reactive protein (hs-CRP) to assess inﬂammation were
measured every six months. Results. BP, HbA1c levels, albumin:creatinine ratios, CIMT, PAT, and hs-CRP did not diﬀer over
a mean of 12 months between the two groups. Conclusions. Aggressive inhibition of the RAS is unnecessary to treat MA.
1.Introduction
Inhibition of the renin angiotensin system (RAS) in dia-
betic patients with microalbuminuria (MA) retards the
developmentofclinicalproteinuria(macroalbuminuria)and
increases the return to normoalbuminuria [1], even in
those who are normotensive [2, 3]. MA is associated with
cardiovascular disease (CVD) [4]a sw e l la si t sp o s t u l a t e d
forerunners, inﬂammation [5], and endothelial dysfunction
[5]. At least one study shows that lowering MA leads to less
CVD [6]. Although to the best of our knowledge there are no
studies evaluating aggressive inhibition of the RAS in type 2
diabetic patients to treat MA, many physicians progressively
increase doses of angiotensin converting enzyme inhibitors
(ACE-I) and angiotensin receptor blockers (ARBs) in these
patients in an attempt to restore normoalbuminuria. This
prospective randomized study compares the eﬀect of aggres-
sive versus low dose inhibition of the RAS on MA, carotid
intima media thickness (CIMT) and endothelial function
as surrogates for CVD [7], and highly sensitive C-reactive
protein (hs-CRP) as a manifestation of inﬂammation.
2. Patients andMethods
Type 2 diabetic patients over the age of 18 years fol-
lowed in the Diabetes Clinics at either Martin Luther
King, Jr-Multi-Service Ambulatory Care Center, or Hubert
Humphrey Comprehensive Health Center who had an
albumin:creatinine ratio of 50–299mg/g were asked to
volunteer for the study. Although the accepted deﬁnition of
microalbuminuriais30to300mg/g,weselectedalowerlimit
of 50mg/g to increase the chances that microalbuminuria
would persist during the run-in period as blood pressure
(BP) and glycemia were controlled since both hypertension
and hyperglycemia can cause microalbuminuria in their own
right [8]. Those who agreed signed an informed consent
approved by the Charles R. Drew University Institutional
Review Board and entered a run-in period.
All patients at screening were receiving benazepril except
one who was taking lisinopril. During the run-in period, the
subjects were switched to 10mg of benazepril per day. BP,
with a target of <130/80mmHg, was treated by the progres-
sive addition of the following classes of drugs with escalating2 ISRN Endocrinology
Screened
Run-in
Randomized
Aggressive
Analyzed Analyzed
1-pregnancy
1-not interested
3-A1C >8%
4-albumin/creatinine ratio <50mg/mg
1-albumin/creatinine ratio >300mg/mg
2-potassium >5.5mEq/L
1-chronic abdominal pain
1-cough with ACE-I
1-systolic BP <100mm Hg
5-reached 18 months
2-grant ended
2-systolic BP <100mm Hg
1-albumin/creatinine ratio >1000mg/g
1-developed cough as ACE-I dose raised
35-repeat albumin/creatinine ratio <50mg/g
15-repeat albumin/creatinine ratio >300mg/g
8-could not be contacted or not interested
1-chronic depression
1-potassium >5.5mEq/L
1-had cough due to ACE-I
2-congestive heart failure
Reason for ending participation
5-reached 18 months
2-grant ended
1-albumin/creatinine ratio >1000mg/g
3-moved
Standard
N = 110
N = 46
N = 27
N = 14 N = 13
N = 11 N = 12
3-lost to followup
1-noncompliant
1-arm too large for 24-hour blood pressure
2 noncompliant before 3 months
Figure 1: Subject ﬂow diagram.
doses in each to a maximum before adding the next class
as necessary; diuretic (hydrochlorothiazide, indapamide,
or furosemide depending on the serum creatinine), beta
blocker (atenolol), and dihydropyridine calcium channel
blocker (amlodipine). Treatment of glycemia was intensiﬁed
ifnecessarybyfollowingdetailedtreatmentalgorithms[9]t o
achieve an HbA1c level of <8.0%. Albumin:creatinine ratios
were measured monthly in morning spot urine samples to
ascertain that the subjects maintained MA as their BP and
glycemia were controlled.
Subjects who met the BP and HbA1c goals and main-
tained MA were randomized into aggressive and low dose
groups and followed for 18 months or until the grant
ended. Albumin:creatinine ratios in morning urine samples
continuedtobemeasuredmonthly.Subjectsintheaggressive
group received increasing doses of benazepril with the
addition of increasing doses of losartan if necessary to
reduce the monthly albumin:creatinine ratios to <30mg/g
as follows: benazepril 10mg to 20mg to 40mg once daily,
plus losartan 25 to 50 to 100mg once daily, and lastly a
second 40mg dose of benazepril at supper. If the systolic
BP fell to <100mmHg as the ACE-I and ARB doses were
increased, doses of the drugs from the other classes were
back-titrated. In the low dose group, benazepril at 10mgISRN Endocrinology 3
Table 1: Characteristics (mean ± SD where applicable) at randomization.
Low dose Aggressive P value
Number of subjects 12 11
Age (years) 54.4 ± 6.7 51.6 ± 5.9 NSa
Males/females 5/7 7/4
Duration of diabetes (years) 12.8 ± 5.4 7.1±3.1 <0.01
Race/ethnicity
Latino 10 10
African American 2 0
Caucasian 0 1
Alb/creat (mg/g) 162.7 ± 94.0 142.2 ± 72.4 NS
Visit systolic BP (mmHg) 126.2 ± 7.1 119.7 ± 10.6 NS
Visit diastolic BP (mmHg) 74.3 ± 10.8 73.4 ± 5.5 NS
24-Hour systolic BP (mmHg) 125.9 ± 6.8 120.9 ± 10.3 NS
24-Hour diastolic BP (mmHg) 73.7 ± 8.7 70.7 ± 4.3 NS
12-Hour AM systolic BP (mmHg) 129.0 ± 6.5 122.0 ± 10.2 NS
12-Hour AM diastolic BP (mmHg) 75.9 ± 8.7 72.2 ± 5.0 NS
12-Hour PM systolic BP (mmHg) 123.1 ± 9.1 119.4 ± 10.6 NS
12-Hour PM diastolic BP (mmHg) 71.7 ± 10.0 69.2 ± 4.8 NS
Body mass index 32.2 ± 5.9 33.7 ± 3.9 NS
HbA1c (%) 7.1 ± 0.6 6.7 ± 0.6 NS
eGFR (mL/min/1.73m2)b 108.7 ± 21.6 100.5 ± 33.7 NS
Right CIMT (mm)b 0.74 ± 0.09 0.72 ± 0.17 NS
Left CIMT (mm)b 0.78 ± 0.16 0.74 ± 0.16 NS
(N = 11) (N = 9)
PAT-Hyperemia-induced (fold increase)b 2.2 ± 0.5 2.0 ± 0.7 NS
PAT-NTG-induced (fold increase)b 1.9 ± 0.8 1.4 ± 0.6 NS
hs-C-reactive proteinb (mg/L)b 4.3 ± 3.6 4.1 ± 3.1 NS
aP>0.05; blog transformed; BP: blood pressure; eGFR: estimated glomerular ﬁltration rate; HbA1c: hemoglobin A1c; CIMT: carotid intima medial thickness;
PAT: peripheral arterial tonometry; hs-CRP: highly sensitive C-reactive protein.
daily was maintained and the anti-hypertensive medications
mentioned above were adjusted based only on BP, not
albumin:creatinine ratios.
All subjects had the following measurements every three
months: HbA1c levels, eGFR utilizing the simpliﬁed modiﬁ-
cation of diet in renal disease (MDRD) equations [10], hs-
CRP, and 24-hour ambulatory BP; every six months, CIMT
[11] and peripheral arterial tonometry (PAT) measuring
reactive hyperemia (RH) via ﬁnger plethysmography to
evaluateendothelial function[12].RH-PAT,whichcorrelates
signiﬁcantly with posthyperemia brachial artery ultrasound
measurements [13] and reﬂects nitric oxide generation [14],
was expressed as the ratio of the pulse wave amplitude rela-
tive to the baseline and normalized to the control arm. We
also measured the response to 0.4mg sublingual nitroglycer-
ine (NTG) given 20 minutes after cuﬀ deﬂation. The NTG-
PAT was expressed as the ratio of the average of the highest
value and the ones just preceding and succeeding it within
the next 15 minutes after cuﬀ deﬂation to the baseline value
before cuﬀ inﬂation again normalized to the control arm.
Baselinecomparisonsbetweenthetwostudygroupswere
performedusingaWilcoxonrank-sumtestwitha5%signiﬁ-
cance level. The evaluation of the data for each measurement
over time was based on the two group repeated measures
Table 2: Medications.
Medications Low dose Aggressive
(N = 12) (N = 11)
Randomization Final Randomization Final
Anti-hypertensives
Benazepril 12 12 11 11
Losartan 0 0 0 10
Diuretica 61 07 3
Amlodipine 3 4 2 4
Atenolol 0 0 4 4
Anti-hyperglycemics
M e t f o r m i n 1 21 21 11 1
Sulfonylureab 7788
Pioglitazone 5 5 4 3
Insulin 6 7 4 4
aHydrochlorothiazide, indapamide, or furosemide; bglyburide, glipizide, or
glimepiride.
analysis of variance. To use this parametric approach, four
of the variables (eGFR, CIMT, PAT, and hs-CRP) were
log-transformed to achieve approximate normality. The4 ISRN Endocrinology
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Figure 2: Responses after randomization; (a) albumin:creatinine ratio; (b) visit systolic BP; (c) visit diastolic BP; (d) HbA1c level; (e)
estimated glomerular ﬁltration rate; (f) right CIMT; (g) left CIMT; (h) reactive hyperemia-induced peripheral arterial tonometry; (i)
nitroglycerine-induced peripheral arterial tonometry; (j) highly sensitive C-reactive protein. The number of subjects followed at each three
month interval in the aggressive- and low-dose groups, respectively, were three months-11 and 12; six months-9 and 11, nine months-8 and
9, 12 months 6 and 6; 15 months-6 and 6; and 18 months-5 and 5. Standard:low dose. Data in graphs (a), (b), (c), and (e) were measured
monthly but shown bimonthly for ease of presentation.ISRN Endocrinology 5
analysis was a modiﬁed intention to treat once a subject
had measurements at three months.
3. Results
One hundred ten patients with MA were identiﬁed but 64
failed to reach the run-in period for the reasons shown in
Figure 1. The most common reason was that on repeat urine
testing for MA, 35 had values <50mg/g and 15 had clinical
proteinuria (>300mg/g) attesting to the marked variation in
day-to-dayurinaryalbuminexcretion whichhasa coeﬃcient
of variation of nearly 33% [15]. Forty-six entered the run-in
period but 19 failed to reach randomization for reasons also
shown in Figure 1. Twenty-seven patients were randomized
but two in each group were noncompliant within the ﬁrst
three months and were dropped from the study. This left
11 subjects in the aggressive group and 12 in the standard
group. The reasons for ending participation after at least
threemonthsofrandomization in eachgrouparealsoshown
in Figure 1. The mean duration of the study in each group
was 12 months.
There were no signiﬁcant diﬀerences at randomization
between the two groups at randomization (Table 1)e x c e p t
that in the aggressive group the duration of diabetes was
signiﬁcantly less than in the low dose group. Medications at
randomization and at the conclusion of the study are shown
inTable 2.Intheaggressivegroupattheﬁnalvisit,sevenwere
taking 80mgbenazepril, four40mgbenazepril, eight 100mg
losartan, and two 50mg losartan. As expected, because the
subjects were brought under control to HbA1c levels <8.0%
before randomization, there was little change in the anti-
hyperglycemic medications during the study. Figure 2 shows
the responses in the two groups over time. There were no
diﬀerences in albumin:creatinine ratios, visit systolic and
diastolic BPs, HbA1c levels, eGFR, CIMTs, or RH-PAT and
NTG-PAT. Twenty-four-hour BPs, whether analyzed over
the entire period or in daytime and nighttime 12-hour
periods, showed the same results, that is, no diﬀerence in
systolic or diastolic BPs (data not shown). One subject in
each group returned to normoalbuminuria, three subjects
in the aggressive group and one in the low dose group
developed clinical proteinuria leading to one in each group
being discontinued because their albumin:creatinine ratios
exceededonegramintwoconsecutiveurinesamplesaftersix
months.
4. Discussion
The eﬀect of aggressive inhibition of the RAS system per
se on microalbuminuria could be reliably evaluated because
glycemia and BP were controlled before randomization and
throughout the study (Figures 2(b), 2(c),a n d2(d)). One
might have expected that the shorter duration of diabetes in
the aggressively treated group might have favored the return
of MA to normoalbuminuria but that was not the case.
Aggressive inhibition of the RAS had no beneﬁcial eﬀect on
MAcomparedtolowdoseinhibition(Figure 2(a)).Although
an obvious limitation of the study is the small number of
subjects, the albuminuria responses make it very unlikely
that more subjects or an extended period of observation
would show a beneﬁcial eﬀect of high doses of an ACE-I
plus an ARB because MA was worsening in the aggressive
group after 10 months (Figure 2(a)). These data extend the
results of the IMPROVE trial in which a submaximal dose
of an ACE-I plus a maximal dose of an ARB was no more
eﬀective in reducing MA than the submaximal dose of the
ACE-I alone [16]. They are also consistent with results in
normotensive type 1 diabetic patients with MA in which
there was no diﬀerence in progression to macroalbuminuria
over two years in those receiving 1.5mg or 5.0mg of ramipril
[17].
The present results do not invalidate the overwhelming
evidence that inhibition of the RAS retards the development
of overt nephropathy in patients with MA [1] because these
subjects had already been treated with varying doses of an
ACE-I for many years before enrolling in the study. It does
show that more aggressive inhibition is ineﬀective. Thus,
physicianscaringforpatientswithMAneedonlyprovidelow
doses of an ACE-I or an ARB for treating MA and control
both BP (with other antihypertensive medications if they
desire) and glycemia for possible further reductions in MA.
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